Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5311 AL 5325

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, de Takacsy F, Schecter R; EMBRACE investigators.

Curr Med Res Opin. 2013 Aug;29(8):989-1000. doi: 10.1185/03007995.2013.802230. Epub 2013 May 23.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.

β-Arrestins as potential therapeutic targets for Alzheimer's disease

Jiang T, Yu JT, Tan MS, Zhu XC, Tan L.

Mol Neurobiol. 2013 Dec;48(3):812-8. doi: 10.1007/s12035-013-8469-8. Epub 2013 May 16.

Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story

Stamford A, Strickland C.

Curr Opin Chem Biol. 2013 Jun;17(3):320-8. doi: 10.1016/j.cbpa.2013.04.016. Epub 2013 May 14.

Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?

Sarazin M, Dorothée G, de Souza LC, Aucouturier P.

Biol Psychiatry. 2013 Sep 1;74(5):329-32. doi: 10.1016/j.biopsych.2013.04.011. Epub 2013 May 14.

Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine

Hsu YC, Chao CY, Chang HA, Hwang SY, Tzeng NS.

J Neuropsychiatry Clin Neurosci. 2013 Spring;25(2):E25-6. doi: 10.1176/appi.neuropsych.12030063.

An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer's Disease

Guo Q, Zhou Y, Wang CJ, Huang YM, Lee YT, Su MH, Lu J.

Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):363-70. doi: 10.1177/1533317513488907. Epub 2013 May 17.

Prediction models for assessing long-term outcome in Alzheimer's disease: a review

Wattmo C.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):440-9. doi: 10.1177/1533317513488916. Epub 2013 May 20.

[Effectiveness and limitation of newly approved drugs for Alzheimer's disease]

Hattori H.

Seishin Shinkeigaku Zasshi. 2013;115(1):22-31.

Drug development in dementia

Cunningham EL, Passmore AP.

Maturitas. 2013 Nov;76(3):260-6. doi: 10.1016/j.maturitas.2013.04.013. Epub 2013 May 23.

Research progress on natural products from traditional Chinese medicine in treatment of Alzheimer's disease

Gao J, Inagaki Y, Li X, Kokudo N, Tang W.

Drug Discov Ther. 2013 Apr;7(2):46-57.

Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause

Henderson VW.

J Steroid Biochem Mol Biol. 2014 Jul;142:99-106. doi: 10.1016/j.jsbmb.2013.05.010. Epub 2013 May 28.

Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer's disease

Igeta H, Suzuki Y, Motegi T, Sasaki A, Yokoyama Y, Someya T.

Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):680.e9-10. doi: 10.1016/j.genhosppsych.2013.04.007. Epub 2013 Jun 2.

Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia

Bahar-Fuchs A, Clare L, Woods B.

Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD003260. doi: 10.1002/14651858.CD003260.pub2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias